electroCore, Inc.: peers
electroCore, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
United Health Products, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | electroCore, Inc.base ECOR · 🇺🇸 US Percentile in Healthcare Percentile in USA | Microbot Medical Inc. MBOT · 🇺🇸 US Percentile in Healthcare Percentile in USA | United Health Products, Inc. UEEC · 🇺🇸 US Percentile in Healthcare Percentile in USA | Stereotaxis, Inc. STXS · 🇺🇸 US Percentile in Healthcare Percentile in USA | Repro Med Systems KRMD · 🇺🇸 US Percentile in Healthcare Percentile in USA | Harvard Bioscience, Inc. HBIO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Nephros, Inc. NEPH · 🇺🇸 US Percentile in Healthcare Percentile in USA | Milestone Scientific Inc. MLSS · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $75 MOct 30, 2026 · Market data4th of 8 | $75 MOct 29, 2026 · Market data3rd of 8 | $72 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one5th of 8 | $92 MOct 30, 2026 · Market data2nd of 8 | $140 MOct 29, 2026 · Market data1st of 8 | $38 MOct 26, 2026 · Market data6th of 8 | $36 MOct 30, 2026 · Market data7th of 8 | $31 MOct 14, 2026 · Market data8th of 8 | $73 M8 ranked |
| Revenue (Better neither way: ranked highest first) | $32 MFY2025 · SEC4th of 6 | —— | —— | $32 MFY2025 · SEC3rd of 6 | $41 MFY2025 · SEC2nd of 6 | $87 MFY2025 · SEC1st of 6 | $19 MFY2025 · SEC5th of 6 | $9 MFY2025 · SEC6th of 6 | $32 M6 ranked |
| Net income (Higher is better) | $-14 MFY2025 · SEC6th of 8 | $-13 MFY2025 · SEC5th of 8 | $-3 MFY2025 · SEC3rd of 8 | $-22 MFY2025 · SEC7th of 8 | $-3 MFY2025 · SEC2nd of 8 | $-57 MFY2025 · SEC8th of 8 | $1 MFY2025 · SEC1st of 8 | $-6 MFY2025 · SEC4th of 8 | $-9 M8 ranked |
| Employees (Better neither way: ranked highest first) | 83February 1, 2026 · Profile2nd of 5 | 43March 24, 2026 · Profile3rd of 5 | —— | 131December 31, 2025 · Profile1st of 5 | —— | —— | 36December 31, 2025 · Profile4th of 5 | 15December 31, 2025 · Profile5th of 5 | 435 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | +27.2%FY2025 · SEC2nd of 675th85th | ———— | ———— | +20.3%FY2025 · SEC4th of 670th79th | +22.2%FY2025 · SEC3rd of 672nd81st | -8.1%FY2025 · SEC6th of 615th13th | +32.7%FY2025 · SEC1st of 678th87th | +3.9%FY2025 · SEC5th of 634th42nd | +21.3%6 ranked |
| Revenue growth, 3 years a year (Higher is better) | +55.1%FY2025 · SEC1st of 690th96th | ———— | ———— | +4.8%FY2025 · SEC4th of 641st52nd | +13.8%FY2025 · SEC3rd of 662nd77th | -8.6%FY2025 · SEC6th of 614th12th | +23.5%FY2025 · SEC2nd of 676th88th | +0.6%FY2025 · SEC5th of 629th35th | +9.3%6 ranked |
| Earnings per share growth (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | +1000.0%FY2025 · SEConly one with it100th100th | ———— | +1000.0%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | 86.8%FY2025 · SEC1st of 688th95th | ———— | ———— | 52.7%FY2025 · SEC6th of 640th66th | 62.2%FY2025 · SEC3rd of 656th76th | 57.7%FY2025 · SEC5th of 649th72nd | 61.8%FY2025 · SEC4th of 655th76th | 71.5%FY2025 · SEC2nd of 670th84th | 62.0%6 ranked |
| Operating margin (Higher is better) | -41.1%FY2025 · SEC3rd of 634th16th | ———— | ———— | -68.3%FY2025 · SEC6th of 628th13th | -7.2%FY2025 · SEC2nd of 650th30th | -56.1%FY2025 · SEC4th of 630th14th | 6.1%FY2025 · SEC1st of 667th59th | -63.5%FY2025 · SEC5th of 628th13th | -48.6%6 ranked |
| Net margin (Higher is better) | -43.6%FY2025 · SEC3rd of 632nd15th | ———— | ———— | -66.8%FY2025 · SEC6th of 628th12th | -6.4%FY2025 · SEC2nd of 652nd31st | -65.5%FY2025 · SEC5th of 628th12th | 6.3%FY2025 · SEC1st of 672nd65th | -63.8%FY2025 · SEC4th of 628th13th | -53.7%6 ranked |
| Free cash flow margin (Higher is better) | -25.8%FY2025 · SEC3rd of 535th15th | ———— | ———— | -42.5%FY2025 · SEC5th of 529th13th | -1.1%FY2025 · SEC2nd of 550th31st | 6.3%FY2025 · SEC1st of 565th59th | ———— | -32.8%FY2025 · SEC4th of 532nd14th | -25.8%5 ranked |
| Return on equity (Higher is better) | ———— | -32.4%FY2025 · SEC3rd of 652nd23rd | ———— | -221.3%FY2025 · SEC6th of 69th4th | -15.6%FY2025 · SEC2nd of 663rd30th | -147.1%FY2025 · SEC5th of 616th7th | 12.7%FY2025 · SEC1st of 685th73rd | -132.4%FY2025 · SEC4th of 618th8th | -82.4%6 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | ———— | ———— | 18.7×price Oct 30, 2026 · Market dataonly one with it29th49th | ———— | 18.7×— |
| Price to sales (Better neither way: ranked highest first) | 2.0×price Oct 30, 2026 · Market data4th of 633rd48th | ———— | ———— | 3.0×price Oct 30, 2026 · Market data2nd of 644th61st | 3.0×price Oct 29, 2026 · Market data3rd of 644th61st | 0.4×price Oct 26, 2026 · Market data6th of 67th13th | 1.6×price Oct 30, 2026 · Market data5th of 628th43rd | 3.3×price Oct 14, 2026 · Market data1st of 646th64th | 2.5×6 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | 1.0×price Oct 29, 2026 · Market data6th of 619th20th | ———— | 6.8×price Oct 30, 2026 · Market data3rd of 675th83rd | 8.2×price Oct 29, 2026 · Market data2nd of 680th86th | 2.7×price Oct 26, 2026 · Market data5th of 646th59th | 3.5×price Oct 30, 2026 · Market data4th of 655th67th | 11.0×price Oct 14, 2026 · Market data1st of 685th90th | 5.1×6 ranked |
| Free cash flow yield (Higher is better) | -11.0%price Oct 30, 2026 · Market data5th of 741st20th | -17.4%price Oct 29, 2026 · Market data7th of 735th16th | ———— | -15.0%price Oct 30, 2026 · Market data6th of 737th17th | -0.3%price Oct 29, 2026 · Market data2nd of 767th36th | 14.5%price Oct 26, 2026 · Market data1st of 797th93rd | -1.6%price Oct 30, 2026 · Market data3rd of 763rd33rd | -9.5%price Oct 14, 2026 · Market data4th of 743rd21st | -9.5%7 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | ———— | ———— | 2.6×FY2025 · SEConly one with it91st89th | ———— | ———— | 2.6×— |
| Interest cover (Higher is better) | ———— | ———— | -20.6×FY2025 · SEC1st of 234th16th | ———— | ———— | -37.4×FY2025 · SEC2nd of 225th11th | ———— | ———— | -29.0×2 ranked |
| Piotroski F-score (Higher is better) | —— | —— | —— | —— | —— | 5 of 9FY2025 · SEConly one with it | —— | —— | 5.0 of 9— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 8 of 19FY2025 · Scorecard2nd of 8 | 2 of 12FY2025 · Scorecard6th of 8 | 1 of 8FY2025 · Scorecard7th of 8 | 2 of 22FY2025 · Scorecard8th of 8 | 8 of 20FY2025 · Scorecard3rd of 8 | 6 of 23FY2025 · Scorecard4th of 8 | 12 of 21FY2025 · Scorecard1st of 8 | 4 of 20FY2025 · Scorecard5th of 8 | 23% passed8 ranked |
| Valuation checks (Higher is better) | 1 of 5FY2025 · Scorecard4th of 7 | 1 of 4FY2025 · Scorecard3rd of 7 | —— | 0 of 5FY2025 · Scorecard5th of 7 | 0 of 5FY2025 · Scorecard5th of 7 | 3 of 6FY2025 · Scorecard2nd of 7 | 4 of 6FY2025 · Scorecard1st of 7 | 0 of 5FY2025 · Scorecard5th of 7 | 20% passed7 ranked |
| Growth checks (Higher is better) | 5 of 6FY2025 · Scorecard1st of 8 | 0 of 2FY2025 · Scorecard7th of 8 | 1 of 2FY2025 · Scorecard4th of 8 | 1 of 6FY2025 · Scorecard6th of 8 | 4 of 6FY2025 · Scorecard3rd of 8 | 0 of 6FY2025 · Scorecard7th of 8 | 5 of 6FY2025 · Scorecard1st of 8 | 2 of 6FY2025 · Scorecard5th of 8 | 42% passed8 ranked |
| Profitability checks (Higher is better) | 1 of 4FY2025 · Scorecard2nd of 8 | 0 of 3FY2025 · Scorecard5th of 8 | 0 of 2FY2025 · Scorecard5th of 8 | 0 of 5FY2025 · Scorecard5th of 8 | 1 of 5FY2025 · Scorecard3rd of 8 | 0 of 5FY2025 · Scorecard5th of 8 | 2 of 5FY2025 · Scorecard1st of 8 | 1 of 5FY2025 · Scorecard3rd of 8 | 10% passed8 ranked |
| Financial health checks (Higher is better) | 1 of 3FY2025 · Scorecard4th of 8 | 1 of 2FY2025 · Scorecard2nd of 8 | 0 of 3FY2025 · Scorecard8th of 8 | 1 of 3FY2025 · Scorecard4th of 8 | 2 of 3FY2025 · Scorecard1st of 8 | 2 of 5FY2025 · Scorecard3rd of 8 | 1 of 3FY2025 · Scorecard4th of 8 | 1 of 3FY2025 · Scorecard4th of 8 | 33% passed8 ranked |
| Shareholder returns checks (Higher is better) | 0 of 1FY2025 · Scorecard3rd of 8 | 0 of 1FY2025 · Scorecard3rd of 8 | 0 of 1FY2025 · Scorecard3rd of 8 | 0 of 3FY2025 · Scorecard3rd of 8 | 1 of 1FY2025 · Scorecard1st of 8 | 1 of 1FY2025 · Scorecard1st of 8 | 0 of 1FY2025 · Scorecard3rd of 8 | 0 of 1FY2025 · Scorecard3rd of 8 | 0% passed8 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 15.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 17.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 0.1%2026-Q2 · 13F8th of 8 | 41.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 46.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 30.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 23.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 5.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 20.6%8 ranked |
| Institutions holding (Better neither way: ranked highest first) | 402026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 742026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 12026-Q2 · 13F8th of 8 | 1022026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 852026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 302026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 322026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 388 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | +1.4 pp2026-Q2 against 2026-Q1 · 13F2nd of 8 | -4.3 pp2026-Q2 against 2026-Q1 · 13F8th of 8 | 0.0 pp2026-Q2 against 2026-Q1 · 13F3rd of 8 | -0.9 pp2026-Q2 against 2026-Q1 · 13F6th of 8 | -0.3 pp2026-Q2 against 2026-Q1 · 13F4th of 8 | +26.7 pp2026-Q2 against 2026-Q1 · 13F1st of 8 | -1.5 pp2026-Q2 against 2026-Q1 · 13F7th of 8 | -0.3 pp2026-Q2 against 2026-Q1 · 13F5th of 8 | -0.3 pp8 ranked |
| Dividends | |||||||||
| Dividend yield (Higher is better) | ———— | ———— | ———— | 0.0%FY2025 · SEConly one with it6th2nd | ———— | ———— | ———— | ———— | 0.0%— |
| Shareholder yield (Higher is better) | ———— | ———— | ———— | 0.0%FY2025 · SEConly one with it7th3rd | ———— | ———— | ———— | ———— | 0.0%— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = electroCore, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Microbot Medical Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; United Health Products, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Stereotaxis, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Repro Med Systems: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Harvard Bioscience, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Nephros, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Milestone Scientific Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| electroCore, Inc. | -41.1%FY2025 | 34th percentile in Healthcaremedian -7.7%, 674 companies | 16th percentile in USAmedian 3.5%, 2,594 companies |
| Microbot Medical Inc. | — | — | — |
| United Health Products, Inc. | — | — | — |
| Stereotaxis, Inc. | -68.3%FY2025 | 28th percentile in Healthcaremedian -7.7%, 674 companies | 13th percentile in USAmedian 3.5%, 2,594 companies |
| Repro Med Systems | -7.2%FY2025 | 50th percentile in Healthcaremedian -7.7%, 674 companies | 30th percentile in USAmedian 3.5%, 2,594 companies |
| Harvard Bioscience, Inc. | -56.1%FY2025 | 30th percentile in Healthcaremedian -7.7%, 674 companies | 14th percentile in USAmedian 3.5%, 2,594 companies |
| Nephros, Inc. | 6.1%FY2025 | 67th percentile in Healthcaremedian -7.7%, 674 companies | 59th percentile in USAmedian 3.5%, 2,594 companies |
| Milestone Scientific Inc. | -63.5%FY2025 | 28th percentile in Healthcaremedian -7.7%, 674 companies | 13th percentile in USAmedian 3.5%, 2,594 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | electroCore, Inc. | Microbot Medical Inc. | United Health Products, Inc. | Stereotaxis, Inc. | Repro Med Systems | Harvard Bioscience, Inc. | Nephros, Inc. | Milestone Scientific Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | $32 MSEC4th | — | — | $32 MSEC3rd | $41 MSEC2nd | $87 MSEC1st | $19 MSEC5th | $9 MSEC6th |
| 2024 | $25 MSEC4th | — | — | $27 MSEC3rd | $34 MSEC2nd | $94 MSEC1st | $14 MSEC5th | $9 MSEC6th |
| 2023 | $16 MSEC4th | — | — | $27 MSEC3rd | $29 MSEC2nd | $112 MSEC1st | $14 MSEC5th | $10 MSEC6th |
| 2022 | $9 MSEC6th | — | $0 MSEC7th | $28 MSEC2nd | $28 MSEC3rd | $113 MSEC1st | $10 MSEC4th | $9 MSEC5th |
| 2021 | $5 MSEC6th | — | $0 MSEC7th | $35 MSEC2nd | $23 MSEC3rd | $119 MSEC1st | $10 MSEC5th | $10 MSEC4th |
| 2020 | $4 MSEC6th | — | $0 MSEC7th | $27 MSEC2nd | $24 MSEC3rd | $102 MSEC1st | $9 MSEC4th | $5 MSEC5th |
| 2019 | $2 MSEC6th | — | $0 MSEC7th | $29 MSEC2nd | $23 MSEC3rd | $116 MSEC1st | $10 MSEC4th | $8 MSEC5th |
| 2018 | $1 MSEC6th | — | $0 MSEC7th | $29 MSEC2nd | $17 MSEC3rd | $121 MSEC1st | $6 MSEC5th | $10 MSEC4th |
| 2017 | $1 MSEC5th | — | $0 MSEC6th | $31 MSEC2nd | — | $77 MSEC1st | $4 MSEC4th | $11 MSEC3rd |
| 2016 | — | — | $0 MSEC6th | $32 MSEC2nd | $12 MSEC3rd | $105 MSEC1st | $2 MSEC5th | $10 MSEC4th |
| 2015 | — | $0 MSEC6th | — | $38 MSEC2nd | $12 MSEC3rd | $109 MSEC1st | $2 MSEC5th | $9 MSEC4th |
| 2014 | — | — | $0 MSEC6th | $35 MSEC2nd | $11 MSEC3rd | $109 MSEC1st | $2 MSEC5th | $10 MSEC4th |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of electroCore, Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Microbot Medical Inc.MBOT · 🇺🇸 USASame industry: Medical Instruments · Similar size: $75 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $75 M (Oct 29, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- United Health Products, Inc.UEEC · 🇺🇸 USASame industry: Medical Instruments · Similar size: $72 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $72 M (last known, Jul 30, 2023)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Stereotaxis, Inc.STXS · 🇺🇸 USASame industry: Medical Instruments · Similar size: $92 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $92 M (Oct 30, 2026) · revenue $32 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Repro Med SystemsKRMD · 🇺🇸 USASame industry: Medical Instruments · Similar size: $140 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $140 M (Oct 29, 2026) · revenue $41 M (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)In the group
- Harvard Bioscience, Inc.HBIO · 🇺🇸 USASame industry: Medical Instruments · Similar size: $38 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $38 M (Oct 26, 2026) · revenue $87 M (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)In the group
- Nephros, Inc.NEPH · 🇺🇸 USASame industry: Medical Instruments · Similar size: $36 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $36 M (Oct 30, 2026) · revenue $19 M (year to December 2025)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)In the group
- Milestone Scientific Inc.MLSS · 🇺🇸 USASame industry: Medical Instruments · Similar size: $31 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $31 M (Oct 14, 2026) · revenue $9 M (year to December 2025)94 of 100 (industry or sector 50 + size 24 + country 15 + figures on file 5)In the group
- Utah Medical Products, Inc.UTMD · 🇺🇸 USASame industry: Medical Instruments · Similar size: $190 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $190 M (Oct 30, 2026) · revenue $39 M (year to December 2025)94 of 100 (industry or sector 50 + size 24 + country 15 + figures on file 5)+ Add
- Daxor CorporationDXR · 🇺🇸 USASame industry: Medical Instruments · Similar size: $61 M market cap against $75 M · Same country: USAMarket cap $61 M (Aug 1, 2026) · revenue $1 M (year to December 2011)94 of 100 (industry or sector 50 + size 29 + country 15)+ Add
- Pro-Dex, Inc.PDEX · 🇺🇸 USASame industry: Medical Instruments · Similar size: $199 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $199 M (Oct 28, 2026) · revenue $78 M (year to June 2026)94 of 100 (industry or sector 50 + size 24 + country 15 + figures on file 5)+ Add
- InfuSystems HoldingsINFU · 🇺🇸 USASame industry: Medical Instruments · Similar size: $255 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $255 M (Sep 28, 2026) · revenue $143 M (year to December 2025)92 of 100 (industry or sector 50 + size 22 + country 15 + figures on file 5)+ Add
- OraSure Technologies, Inc.OSUR · 🇺🇸 USASame industry: Medical Instruments · Similar size: $262 M market cap against $75 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $262 M (Oct 23, 2026) · revenue $115 M (year to December 2025)92 of 100 (industry or sector 50 + size 22 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.